

PrEP and Sex Work Reference List

Abdool Karim, Q ; Abdool Karim, S; and others. (2010) Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women *Science* 3 September 2010: Vol. 329 no. 5996 pp. 1168-1174 **CO**

Adam, BD. (2011). Epistemic fault lines in biomedical and social approaches to HIV prevention. *Journal of the International AIDS Society* 14 (2) **CO**

Campbell, C; Cornish D. (2010) Towards a "fourth generation" of approaches to HIV/AIDS management: creating contexts for effective community mobilization. *AIDS Care*.;22 Suppl 2:1569-79 **CO**

Campbell, J. D., Herbst, J. H., Koppenhaver, R. T., & Smith, D. K. (2013). Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S63-S69. **DA**

Canadian Public Health Association. (2011) Preparing Public Health for New HIV Prevention Technologies: A Road Map for Comprehensive Action in Canada Available at http://www.cpha.ca/uploads/progs/infectious/npt-hiv_e.pdf Accessed 18.12/12 **CO**

CASAM (2008) Rights-Based Sex Worker Empowerment Guidelines: An Alternative HIV/AIDS Intervention Approach to the 100% Condom Use Programme, p 5. Available at <http://www.plri.org/resource/rights-based-sex-worker-empowerment-guidelines-alternative-100-condom-use-programme>. Accessed 20/12/12 **CO**

Cassell, MC; Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention? *BMJ* 2006;332:605- 607. **CO**

Cohen, S. E., Liu, A. Y., Bernstein, K. T., & Philip, S. (2013). Preparing for HIV pre-exposure prophylaxis: Lessons learned from post-exposure prophylaxis. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S80-S85. **CODA**

Culp, L., & Caucci, L. (2013). State adolescent consent laws and implications for HIV pre-exposure prophylaxis. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S119-S124. **DA**

Curran, J. W., & Crosby, R. A. (2013). Pre-exposure prophylaxis for HIV: Who will benefit and what are the challenges? *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S163-S166. **DA**

Day, S; Ward, H. (1997) Sex workers and the control of sexually transmitted disease. *Genitourin Med* 73:161-168 **CO**

Dearing, J. W., Norton, W. E., & Larson, R. S. (2013). Next steps in designing for diffusion of pre-exposure prophylaxis: Demonstration projects. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S156-S160. **DA**

Dearing, J. W., Smith, D. K., Larson, R. S., & Estabrooks, C. A. (2013). Designing for diffusion of a biomedical intervention. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S70-S76. **DA**

Ditmore, M; Allman D. (2012). Who is Helsinki?' Sex workers advise improving communication for good participatory practice in clinical trials. *Health Education Research Advance Access*. **CO**

Dutta, MJ. (2013). Disseminating HIV Pre-Exposure Prophylaxis Information in Underserved Communities. *J American Journal of Preventative Medicine*, 44: S133- DOI: 10.1016/j.amepre.2012.09.030 **DA**

Eaton, L; Kalichman,S. (2007). Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies. *21. Current HIV/AIDS Reports*. 4 (4), 165-172. **CO**

Edelman, E. J., & Fiellin, D. A. (2013). Moving HIV pre-exposure prophylaxis into clinical settings: Lessons from buprenorphine. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S86-S90. **CODA**

Editorial board.(2013). *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), A1-A2. **DA**

Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, et al. (2012) Attitudes and Acceptance of Oral and Parenteral HIV Preexposure Prophylaxis among Potential User Groups: A Multinational Study. *PLoS ONE* 7(1): e28238. doi:10.1371/journal.pone.0028238 **DA**

ElZarrad, M. K., Eckstein, E. T., & Glasgow, R. E. (2013). Applying chronic illness care, implementation science, and self-management support to HIV. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S99-S107. **DA**

Essack, Z; Koen, J; Slack, C; Lindegger, G; Newman, PA. (2012). Civil society perspectives on negative biomedical HIV prevention trial results and implications for future trials. *AIDS CARE- Psychological And Socio-Medical Aspects Of AIDS/HIV*. 24 (10), 1249-1254. **CO**

Folayan, M O; Falobi, O; Faleyimu, B; Ogunlayi, M. (2011). Standard of care for HIV prevention technology research: a consensus document from Nigeria. *African journal of medicine and medical sciences*. 40 (3), 265-71 **CO**

Foss, AM; Vickerman, PT; Alary, M; Watts, CH; (2009). How much could a microbicide's sexually transmitted infection efficacy contribute to reducing HIV risk and the level of condom use needed to lower risk? Model estimates. *Sex Transm Infect*. 85 (4) **CO**

Foss, AM; Vickerman, PT; Heise, L; Watts, CH. (2005). Shifts in condom use following microbicide introduction: should we be concerned ? *AIDS*. 19 (4), 413-21. **CO**

Forbes A. (2011) New prevention technologies and their implications. Available at: <http://www.nswp.org/sites/nswp.org/files/New%20Prevention%20Technologies.pdf>. [Accessed 12 December 2012]. **CO**

Forbes A, Mudaliar S. (2009). *Preventing prevention trial failures: A case study and lessons for future trials from the 2004 tenofovir trial in Cambodia*. Global Campaign for Microbicides; Available from <http://www.global-campaign.org/clientfiles/Cambodia.pdf> **CO**

Galea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, Sayles JN, Cáceres C and Cunningham WE. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations *Int J STD AIDS* 2011 22: 256 **DA**

Galinda, G. (2012). Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. *Implementation Science*. 7 (28), 116. **CO**

Gomez GB, Borquez A, Cáceres CF, Segura ER, Grant RM, et al. (2012) The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study. *PLoS Med* 9(10): e1001323. doi:10.1371/journal.pmed.1001323 **DA**

Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EEK, Chen PL, and MacQueen KM. (2010). Acceptability of PrEP for HIV Prevention Among Women at High Risk for HIV. *Journal of Women's Health*, 19(4): 791-798. doi:10.1089/jwh.2009.1576. **DA**

Grant R. (2010). Pre-exposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. *N Engl J Med*. 363 (27), 2587–2599. **CO**

Grobler, AC; Karim, S. (2012). Design challenges facing clinical trials of the effectiveness of new HIV-prevention technologies. *AIDS*. 26, 529-532. **CO**

Haire, B. and Kaldor, J. M. (2013), Ethics of ARV Based Prevention: Treatment-as-Prevention and PrEP. *Developing World Bioethics*, 13: 63–69. doi: 10.1111/dewb.12026 **DA**

Hankins, CA; Dybul, MR. (2013) The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. *Curr Opin HIV AIDS*. 2013 Jan;8(1):50-8. **CO**

Haynes, BF.; Liao, HX; Tomaras, GD. (2010). Is developing an HIV-1 vaccine possible? *Current Opinion in HIV AND AIDS*. 5 (5), 362-367. **CO**

Heise, Lori L; Watts, C; Foss, A; Trussell, J; Vickerman, P; Hayes, R; McCormack, S. (2011). Apples and oranges? Interpreting success in HIV prevention trials. *CONTRACEPTION*. 83 (1), 10-15. **CO**

Hilber, A M; Kenter, E; Redmond, S; Merten, S; Bagnol, B; Low, N; Garside. (2012). Vaginal practices as women's agency in Sub-Saharan Africa: A synthesis of meaning and motivation through meta-ethnography *Social Science & Medicine*. 74, 1311-1323. **CO**

Horberg, M., & Raymond, B. (2013). Financial policy issues for HIV pre-exposure prophylaxis: Cost and access to insurance. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S125-S128. **DA**

Hosek, S. G. (2013). HIV pre-exposure prophylaxis diffusion and implementation issues in nonclinical settings. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S129-S132. **DA**

Human Rights Watch (2012) Sex Workers at Risk Condoms as Evidence of Prostitution in Four US Cities. Available at <http://www.hrw.org/reports/2012/07/19/sex-workers-risk> Accessed 4/113 **CO**

International Committee of Aids Service Organisations. ICASO (2007) Barriers to Condom Access: setting an advocacy agenda. Available at http://www.icaso.org/publications/condom_access2007_eng.pdf. Accessed 20/12/12 **CO**

Imrie, J; Jonathan, E; Kippax, S. (2012) Biomedical prevention interventions offer large promise, but are not a panacea. *European Aids Treatment Group*. [available at http://www.eatg.org/news/165049/Biomedical_HIV_prevention%E2%80%94and_social_science] accessed 12/12/12 **CO**

Jackson T, Huang A , Chen H , Gao X , Zhang Y & Zhong X. (2013). Predictors of Willingness to use HIV pre-exposure prophylaxis among female sex workers in Southwest China, *AIDS Care: Psychological and Socio-medical Aspects of AIDS/HIV*, 25:5, 601-605, DOI: 10.1080/09540121.2012.726341 **DA**

Kacaneck, D; Dennis, A; Sahin-Hodoglugil, Nuriye Nalan; Montgomery; Morar, N; Mtetwa, S; Nkala, B; Phillip, J; Watadzaushe, C; van der Straten, A. (2012). A qualitative study of obstacles to diaphragm and condom use in an HIV prevention trial in Sub-saharan Africa. *Aids Education and Prevention*. 24 (1), 54-67. **CO**

Georges EK, Luiz JM. From trials to the public health: pre-exposure prophylaxis for HIV prevention. *Colomb. Med.* [serial on the Internet]. 2013 Jan [cited 2013 Nov 06]; 44(1): 64-65. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S1657-95342013000100012&lng=en. **DA**

Kane, R. (2012). Framing Responsibility HIV, Biomedical Prevention, and the Performativity of the Law. *Journal Of Bioethical Inquiry*. 9 (SI), 327-338. **CO**

Katz, M. H. (2013). Pre-exposure prophylaxis for HIV: Can it be implemented in the real world? *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S161-S162. **DA**

Kempner, J. (2008) The Chilling Effect: How Do Researchers React to Controversy? (2011) Available at <http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0050222> Accessed 20/12/12 **CO**

Kenworthy, N. J. and Bulled, N. (2013), From modeling to morals: Imagining the future of HIV PREP in Lesotho. *Developing World Bioethics*, 13: 70–78. doi: 10.1111/dewb.12029 **DA**

Kippax S; Holt M; Friedman S. (2012). Bridging the social and the biomedical: engaging the social and political sciences in HIV research. Introduction to special supplement of *Journal of the International AIDS Society* 14 (2) **CO**

- Kippax, S; Reis, E; de Wit, J. (2011). Two Sides to the HIV Prevention Coin: Efficacy And Effectiveness. *Aids Education And Prevention*. 23 (5), 393-396 **CO**
- Kiser, PF; Johnson, T; Clark, JT.(2012). State of the Art in Intravaginal Ring Technology for Topical Prophylaxis of HIV Infection. *AIDS REVIEWS*. 14 (1), 62-77. **CO**
- Knerr, W; Philpott, A. (2011). Strange bedfellows: bridging the worlds of academia, public health and the sex industry to improve sexual health outcomes. *Health Research Policy and Systems*. 9 (S13) **CO**
- Kokolo MB, Fergusson DA, Cameron DW (2011) HIV Pre-Exposure Prophylaxis (PrEP)—A Quantitative Ethics Appraisal. *PLoS ONE* 6(8): e22497. doi:10.1371/journal.pone.0022497 **DA**
- Koenig, L. J., Lyles, C., & Smith, D. K. (2013). Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: Lessons learned from trials and treatment studies. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S91-S98. **DA**
- Kumar SG, Anil Kumar G, Poluru R, Schneider JA, Dandona L, Vemu L, et al. Contact with HIV prevention programmes & willingness for new interventions among truckers in India. *Indian J Med Res*. 2013;137:1061–71. [PMCID: PMC3734711] [PubMed: 23852287] **DA**
- Laga, M; Piot, P. (2012). Prevention of sexual transmission of HIV: real results, science progressing, societies remaining behind. *AIDS*. 26, 1223-1229. **CO**
- Lagakos, S; Gable, A. (2008) Challenges to HIV Prevention — Seeking Effective Measures in the Absence of a Vaccine *N Engl J Med* 2008; 358:1543-1545_ **CO**
- Lancet Editorial. (2011). HIV treatment as prevention—it works. *The Lancet* . 377 (9779), 1719. **CO**
- Lin, H.(2009). Microbicide Acceptability among Female Sex Workers in Beijing, China: Results from a Pilot Study. *J Womens Health* . 18 (9), 1377–1384. **CO**
- Lowe, D. (2003) “Perceptions of the Cambodian 100% Condom Use Program: Documenting the experience of sex workers,” Report to the Policy Project. **CO**
- MacQueen KM (2011) Framing the social in biomedical HIV prevention trials: a 20-year retrospective. *Journal of the International AIDS Society* 2011, 14(Suppl 2):S3. **CO**
- Malotte, C. K. (2013). Brief risk-reduction counseling in clinical settings for HIV pre-exposure prophylaxis. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S112-S118. **DA**
- Mallipeddi, R; Rohan, L. (2010). Nanoparticle-based vaginal drug delivery systems for HIV prevention. *Expert Opinion on Drug Delivery*. 7 (1), 37-48. **CO**
- Mantell, JE; Stein, ZA; Susser, I. (2008). Women in the time of AIDS: Barriers, bargains, and benefits. *Aids Education And Prevention*. 20 (2), 91-106. **CO**

May, M. (2009). New technologies promise safer sex for women. *Nature Medicine*. 15 (9), 979. **CO**

Mensch BS, van der Straten A, Katzen LL. Acceptability in microbicide and PrEP trials: current status and a reconceptualization. *Curr Opin HIV AIDS*. 2012 Nov;7(6):534-41. doi: 10.1097/COH.0b013e3283590632. **DA**

Moodley K. (2007) Microbicide research in developing countries: have we given the ethical concerns due consideration? *BMC Medical Ethics*, 8:10. **CO**

Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, et al. (2012) Safety and Adherence to Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex Workers. *PLoS ONE* 7(4): e33103. doi:10.1371/journal.pone.0033103 **DA**

Norton, W. E., Larson, R. S., & Dearing, J. W. (2013). Primary care and public health partnerships for implementing pre-exposure prophylaxis. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S77-S79. **DA**

Orner, P; Harries, J; Cooper, D; Moodley, M; Hoffman, J and others. (2006) Challenges to microbicide introduction in South Africa *Social Science & Medicine*, Volume 63, Issue 4, 968-978 **CO**

Overs C, (2007) Sex Work and the New Era of HIV Prevention and Care. APNSW <http://www.eldis.org/assets/Docs/44838.html>Overs, C. (2012) **CO**

Overs, C. (2011) Treatment as Prevention: How might the game change for sex workers? Paulo Longo Research Initiative Newsletter. 1. Available Online at <http://www.plri.org/newsletter/newsletter-number-1>[Accessed 12 December 2012]. **CO**

Overs, C. (2012) HIV drugs for prevention: a game changer for sex workers ? The Conversation <http://theconversation.edu.au/profiles/cheryl-overs-8548> **CO**

Overs, C. (2012) The Tide Cannot Be Turned Without Us. Plenary Presentation at AIDS 2012 transcript and video available at <http://pag.aids2012.org/session.aspx?s=677#2> and in summary in Research for Sex Work 13 2012 available at <http://www.nswp.org/news-story/research-sex-work-13-hiv-and-sex-work-%E2%80%93-the-view-2012> . accessed 21/12/12 **CO**

Padian NS, Buve A, Balkus J, Serwadda D, Cates W: (2008) Biomedical interventions to prevent HIV infection: evidence, challenges and way forward. *Lancet*, 372:585–99. **CO**

Padian N, McCoy S, Abdool Karim S, Hasen N, Kim J, Bartos M, Katabira E, Bertozzi S, Schwartländer S, Cohen M. (2011). HIV prevention transformed: the new prevention research agenda. *The Lancet*. 378 (9787), 269-278. **CO**

Padian NS, McCoy SI, Balkus JE. (2010). Weighing the gold in the gold standard: challenges in HIV prevention research. *AIDS* 24:621-635. DOI: 10.1097/QAD.0b013e328337798a **DA**

Patton C, Kim HJ. The Cost of Science Knowledge and Ethics in the HIV Pre-Exposure Prophylaxis Trials. (2012) *Journal of Bioethical Inquiry*, 9: 295-310. 310 DOI: 10.1007/s11673-012-9383-x **DA**

Peng B, Yang X., Zhang Y., Dai J, Liang H., Zou Y, Luo J, Peng H., Zhong X , and Ailong Huang, A. Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China *HIV AIDS (Auckl)*. 2012; 4: 149–158. Published online 2012 September 24. doi: 10.2147/HIV.S33445 PMID: PMC3463398 **DA**

Peters, A; Jansen, W; van Driel, F. (2010). The female condom: the international denial of a strong potential. *Reproductive Health Matters*. 18 (35), 119-128 **CO**

Peterson, L. (2007). Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. *PLoS Clinical Trials*. 2 (5), 27. **CO**

Philpott, S. (2013). Social justice, public health ethics, and the use of HIV pre-exposure prophylaxis. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S137-S140. **CODA**

Poynten, IM; Jin, F.; Prestage, G. P.; Kaldor, J. M.; Imrie, J.; Grulich, A. E. (2010). Attitudes towards new HIV biomedical prevention technologies among a cohort of HIV-negative gay men in Sydney, Australia. *HIV MEDICINE*. 11 (4), 282-288 **CO**

Pretorius C, Stover J, Bollinger L, Bacaër N, Williams B (2010) Evaluating the Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) and Its Impact on HIV-1 Transmission in South Africa. *PLoS ONE* 5(11): e13646. doi:10.1371/journal.pone.0013646 **DA**

Pyett, P; Haste B; Snow J. (1996) Who works in the sex industry? A profile of female prostitutes in Victoria. *Australian and New Zealand Journal of Public Health*, Volume 20, Issue 4, pages 431–433. **CO**

Ramjee, G. (2000). Challenges in the conduct of vaginal microbicide effectiveness trials in the developing world. *AIDS*. 14 (16). **CO**

Roddy, RE; Zekeng, L.; Ryan, KA; Tamoufé, U; Weir ,SS; Wong, EL. (1998) A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. *N Engl J Med*. 1998 Aug 20;339(8):504-10. **CO**

Romano, Joseph; Malcolm, R Karl; Garg, Sanjay; Rohan, Lisa C; Kaptur, Paulina E. (2008). Microbicide delivery: formulation technologies and strategies. *Current opinion in HIV and AIDS*. 3 (5), 558-66. **CO**

Rowniak, S; Portillo, C. Pre-Exposure Prophylaxis: An Ethical Discussion. (2012) *Journal of the Association of Nurses in AIDS Care, In Press, Corrected Proof, Available online accessed 20/12/12* **CO**

Sarazin, V; Milsom, P; Sternthal, S; Patten, S; Leblanc, M. (2010). Mapping of Canadian and International New HIV Prevention Technology Initiatives, Programs, Models and Networks. *Aids Research and Human Retroviruses*. 26 (10), A107-A107. **CO**

Schneider JA, Dandona R, Pasupneti, S. Initial Commitment to Pre-Exposure Prophylaxis and Circumcision for HIV Prevention amongst Indian Truck Drivers. (2010) *PLOS ONE* 5, 7 DOI: 10.1371/journal.pone.0011922 **DA**

Schofield, T; Hepworth, J; Jones, M; Schofield, E. (2011) Health and community services for trafficked women: An exploratory study of policy and practice. *Australian Journal of Social Issues*, Volume 46 Issue 4 (2011) **CO**

Shattock, RJ; Rosenberg, Z. (2012). Microbicides: Topical Prevention against HIV. *Cold Spring Harbor perspectives in medicine*. 2 (2) **CO**

Smith, DJ; Wakasiaka, S; Hoang TD, Bwayo, J; Del Rio, C; Priddy, FH. (2008) An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: Behaviors and attitudes that might influence uptake within a high-risk population. *J Womens Health* . 17, 1025–1034 **CO**

Smith, D. K., & Beltrami, J. (2013). A proposed framework to monitor daily oral antiretroviral pre-exposure prophylaxis in the U.S. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S141-S146. **DA**

Smith, D. K., Dearing, J. W., Sanchez, T., & Goldschmidt, R. H. (2013). Introducing wicked issues for HIV pre-exposure prophylaxis implementation in the U.S. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S59-S62. **DA**

Smith, RJ; Bodine, EN; Wilson, DP; Blower, SM. (2005). Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. *AIDS*. 19 (4), 413-21 **CO**

Stillat, M; Gordon, C. (2008). Adherence to biomedical HIV prevention methods: Considerations drawn from HIV treatment adherence. *Current HIV/AIDS Reports*. 5 (4), 1 **CO**

Table of contents.(2013). *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), A3-A4. **DA**

Thrun, M. W. (2013). Provider-initiated HIV Risk behavior counseling in the context of HIV pre-exposure prophylaxis. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S108-S111. **DA**

Tilson, H. H. (2013). Using registries to monitor HIV pre-exposure prophylaxis safety in clinical settings. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S151-S155. **DA**

Trent-Adams, S., & Cheever, L. W. (2013). Providing HIV pre-exposure prophylaxis: Lessons learned from the Ryan white HIV/AIDS program. *American Journal of Preventive Medicine; Implementing Pre-Exposure Prophylaxis (PrEP) in the U.S. Moving from Evidence to Practice*, 44(1), S147-S150. **DA**

Tyrer L. (1999) Introduction of the pill and its impact. *Contraception*. Jan;59(1 Suppl):11S-16S. **CO**

UNAIDS Joint United Nations Programme on HIV/AIDS & AVAC. (2007) Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials. Available at http://data.unaids.org/pub/Manual/2007/jc1364_good_participatory_guidelines_en.pdf [accessed 20/12/12] **CO**

UNAIDS/WHO (2007) Ethical considerations in biomedical HIV prevention trials Available at http://data.unaids.org/pub/manual/2007/jc1349_ethics_2_11_07_en.pdf. Accessed 1/1/13 **CO**

UNAIDS Guidance Note on HIV and Sex Work. (2009) available at http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2009/JC2306_UNAIDS-guidance-note-HIV-sex-work_en.pdf accessed 20/12/12 **CO**

Underhill K, Operario D, Skeer M, Mimiaga M, Mayer K. (2010). Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice. *J Acquir Immune Defic Syndr*. Sep;55(1):8-13. **DA**

Ukpong, M and Peterson K. (2009) Oral Tenofovir Controversy II: Voices from the Field. A series of reports of the Oral Tenofovir Trials from the perspectives of Active Community Voices engaged on the field in Cambodia, Cameroon, Nigeria, Thailand and Malawi. New HIV Vaccines and Microbicides Advocacy Society (NHVMAS) <http://www.nhvmas-ng.org/publication/TDF2.pdf> **CO**

Vallely A, Shagi C, Lees S, Shapiro K, Masanja J, Nikolau L, Kazimoto J, Soteli S, Moffat C, Changalucha J, . (2008). Microbicides development programme: engaging the community in the standard of care debate in a vaginal microbicide trial in Mwanza, Tanzania. *BMC Med Ethics*. 17 (6), 1025-34 **CO**

Van der Elst EM, Mboua J, Operario D, Mutua G, Kuo C, Mugo P, Kanungi J, Singh S, Haberer J, Priddy F, Sanders EJ. High Acceptability of HIV Pre-exposure Prophylaxis but Challenges in Adherence and Use: Qualitative Insights from a Phase I Trial of Intermittent and Daily PrEP in At-Risk Populations in Kenya. *AIDS Behav* (2013) 17:2162–2172 DOI 10.1007/s10461-012-0317-8 **DA**

van der Straten, A; Montgomery, ET; Cheng, H; Wegner, L; Masenga, G; von Mollendorf, C; Bekker, L; Ganesh, S; Young, K; Romano, J; Nel, A; Woodson, C. (2012). High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. *AIDS and Behaviour*. 16 (7), 1775-86 **CO**

van der Straten, A; Montgomery, E T; Hartmann, M; Minnis, A. (2012) Methodological lessons from clinical trials and the future of microbicide research. *Current Opinions in HIV & AIDS*. [Epub ahead of print accessed 25/12/12 at <http://www.ncbi.nlm.nih.gov/pubmed/23184582> **CO**

Venter, F., Allais, L. and Richter, M. (2013), Exposure Ethics: Does Hiv Pre-Exposure Prophylaxis Raise Ethical Problems for the Health Care Provider and Policy Maker? *Bioethics*. doi: 10.1111/bioe.12021 **DA**

Verguet, S, Stalcup M, Walsh, JA. (2012). Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa? *Sex Transm Infect* doi:10.1136/sextrans-2012-050891 **DA**

Vickerman, P . (2010) Using mathematical modelling to estimate the impact of periodic presumptive treatment on the transmission of sexually transmitted infections and HIV among female sex workers *Sex Transm Infect* 86:163-8. **CO**

Vickerman, P; Watts, C; Delany, S; Alary, M; Rees, H; Heise, L. (2006). The Importance of Context: Model Projections on How Microbicide Impact Could Be Affected by the Underlying Epidemiologic and Behavioral Situation in 2 African Settings. *Sexually Transmitted Diseases* : 33: 397-405. **CO**

Vissers DCJ, Voeten HACM, Nagelkerke NJD, Habbema JDF, de Vlas SJ (2008) The Impact of Pre-Exposure Prophylaxis (PrEP) on HIV Epidemics in Africa and India: A Simulation Study. *PLoS ONE* 3(5): e2077. doi:10.1371/journal.pone.0002077 **CODA**

Walsh, C; Singh, G. (2012). Building the HIVE: disrupting biomedical HIV and AIDS research with gay men, other men who have sex with men (MSM) and transgenders. In: *2012 AERA Annual Meeting*, 13-17 April 2012, Vancouver, Canada Available at http://www.academia.edu/1486605/Building_the_HIVe_Disrupting_Biomedical_HIV_and_AIDS_Research_with_Gay_Men_other_men_who_have_sex_with_men_MSM_and_Transgenders Accessed 21/12/12 **CO**

Warren, M. J. and Bass, E. S. (2013). From Efficacy to Impact An Advocate's Agenda for HIV Pre-Exposure Prophylaxis Implementation. *American Journal of Preventive Medicine*, 44(1S2): S197-S170. **CODA**

Whaley, KJ. Hanes, J, Shattock, R, Cone RA, Friend DR. (2010). Novel Approaches to Vaginal Delivery and Safety of Microbicides: Biopharmaceuticals, Nanoparticles, and Vaccines. *Antiviral Research*. 88 (1) S55-S66. **CO**

Wheelock A, Eisingerich AB, Gomez GB, Gray E, Dybul MR and Piot P. (2012). Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): a multinational qualitative study. *BMJ Open* 2:4 e001234 doi:10.1136/bmjopen-2012-001234 **DA**

Yuen WW, Wong WC, Tang CS, Holroyd E, Tiwari AF, Fong DY, Chin WY. (2013). Evaluating the effectiveness of personal resilience and enrichment programme (PREP) for HIV prevention among female sex workers: a randomized controlled trial. *BMC Public Health*. 13:683. doi: 10.1186/1471-2458-13-683. **DA**